JP2024536581A - 中等度から重度の不安及び/又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療 - Google Patents

中等度から重度の不安及び/又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療 Download PDF

Info

Publication number
JP2024536581A
JP2024536581A JP2024523674A JP2024523674A JP2024536581A JP 2024536581 A JP2024536581 A JP 2024536581A JP 2024523674 A JP2024523674 A JP 2024523674A JP 2024523674 A JP2024523674 A JP 2024523674A JP 2024536581 A JP2024536581 A JP 2024536581A
Authority
JP
Japan
Prior art keywords
cbd
asd
subject
abc
irritability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536581A5 (enExample
Inventor
パルーンボ,ジョーセフ
オクィン,スティーブン・ブイ
Original Assignee
ジナーバ・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジナーバ・ファーマシューティカルズ・インコーポレイテッド filed Critical ジナーバ・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2024536581A publication Critical patent/JP2024536581A/ja
Publication of JP2024536581A5 publication Critical patent/JP2024536581A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024523674A 2021-10-22 2022-10-20 中等度から重度の不安及び/又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療 Pending JP2024536581A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163271015P 2021-10-22 2021-10-22
US63/271,015 2021-10-22
PCT/US2022/078449 WO2023070045A1 (en) 2021-10-22 2022-10-20 Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Publications (2)

Publication Number Publication Date
JP2024536581A true JP2024536581A (ja) 2024-10-04
JP2024536581A5 JP2024536581A5 (enExample) 2025-10-27

Family

ID=84358575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523674A Pending JP2024536581A (ja) 2021-10-22 2022-10-20 中等度から重度の不安及び/又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療

Country Status (10)

Country Link
US (1) US20240342198A1 (enExample)
EP (1) EP4419091A1 (enExample)
JP (1) JP2024536581A (enExample)
KR (1) KR20240093852A (enExample)
CN (1) CN118284412A (enExample)
AU (1) AU2022373753A1 (enExample)
CA (1) CA3235677A1 (enExample)
IL (1) IL312328A (enExample)
MX (1) MX2024004766A (enExample)
WO (1) WO2023070045A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
WO2010127033A1 (en) 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
CA3300266A1 (en) * 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
WO2019224824A1 (en) * 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
JP7856584B2 (ja) * 2020-05-26 2026-05-11 ハーモニー・バイオサイエンシズ・マネージメント・インコーポレイテッド カンナビジオールを用いた自閉症スペクトラム障害の処置
TWI902836B (zh) * 2020-06-29 2025-11-01 美商和諧生物科學管理股份有限公司 以大麻二酚(cannabidiol)治療X染色體脆折症候群
LT4243797T (lt) * 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui

Also Published As

Publication number Publication date
CN118284412A (zh) 2024-07-02
CA3235677A1 (en) 2023-04-27
WO2023070045A1 (en) 2023-04-27
MX2024004766A (es) 2024-06-11
IL312328A (en) 2024-06-01
US20240342198A1 (en) 2024-10-17
AU2022373753A1 (en) 2024-05-09
KR20240093852A (ko) 2024-06-24
EP4419091A1 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
US12226373B2 (en) Treatment of fragile X syndrome with cannabidiol
KR102966746B1 (ko) 우울증 치료를 위한 에스케타민
JP7856584B2 (ja) カンナビジオールを用いた自閉症スペクトラム障害の処置
US12582664B2 (en) Treatment of fragile x syndrome with cannabidiol
US20240342198A1 (en) Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance
US20260027137A1 (en) Treatment of fragile x syndrome with cannabidiol
US20230000793A1 (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
US20230000792A1 (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
US20250177322A1 (en) Treatment of fragile x syndrome with cannabidiol
US20240390295A1 (en) Methods for treating depression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017